AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31667609 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of serum lipids from second to third trimester
Number of subjects: 748
Study 31667609 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of prematurity on serum lipids
Number of subjects: 748
Study 31667659 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (100 mg bid) + Carboplatin (AUC 4)
Number of subjects: 57
Study 31667659 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib + Carboplatin + Paclitaxel
Number of subjects: 57
Study 31667696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose oseltamivir (75 mg for adolescents/adults; 30-75 mg by body weight for children), twice daily for 10 days
Number of subjects: 228
Study 31667696 — intervention group
Group type: COMPARATOR
Intervention: Double-dose oseltamivir (150 mg for adolescents/adults; 60-150 mg for children), twice daily for 10 days
Number of subjects: 228
Study 31667696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose oseltamivir
Number of subjects: 228
Study 31667696 — intervention group
Group type: COMPARATOR
Intervention: Double-dose oseltamivir
Number of subjects: 228
Study 31668140 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 31668348 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ferritin <100 μg L)
Number of subjects: 730
Study 31668380 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional culture
Number of subjects: 200
Study 31668380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid molecular test (Xpert® SA Nasal Complete)
Number of subjects: 200
Study 31668380 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempt to decolonise
Number of subjects: 200
Study 31668516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD)
Number of subjects: 36
Study 31668516 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls who did not receive the PtDA)
Number of subjects: 36
Study 31668571 — intervention group
Group type: EXPERIMENTAL
Intervention: FAINT score of 0
Number of subjects: 3177
Study 31668571 — intervention group
Group type: EXPERIMENTAL
Intervention: FAINT score greater than or equal to 1
Number of subjects: 3177
Study 31668571 — intervention group
Group type: EXPERIMENTAL
Intervention: FAINT score
Number of subjects: 3177
Study 31668571 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day all-cause mortality or serious cardiac outcome
Number of subjects: 3177
Study 31668633 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine PLIN-2 assay
Number of subjects: 0
Study 31668633 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study 31668633 — intervention group
Group type: COMPARATOR
Intervention: Patients with bladder cancer
Number of subjects: 0
Study 31668633 — intervention group
Group type: COMPARATOR
Intervention: Patients with diabetic nephropathy
Number of subjects: 0
Study 31668646 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS on the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 50
Study 31668646 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of sgACC to right DLPFC and rACC to left lateral parietal cortex (IPL)
Number of subjects: 50
Study 31668646 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal rs-fMRI data analyses
Number of subjects: 50
Study 31668825 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) administered prior to induction and prior to post-remission therapy
Number of subjects: 43
Study 31668825 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) measures pre- and post-induction
Number of subjects: 43
Study 31668830 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (15 mg oral)
Number of subjects: 24
Study 31668830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31668830 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 24
Study 31669004 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min steady-state (SS) approach for estimating resting energy expenditure (REE) using indirect calorimetry
Number of subjects: 64
Study 31669004 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-min and 3-min SS periods, or fixed time intervals of at least 5 min
Number of subjects: 64
Study 31669155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (escalating doses of 10 mg once daily to 100 mg twice daily in phase 1 only)
Number of subjects: 69
Study 31669560 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted hernia repair
Number of subjects: 200
Study 31669560 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 200
Study 31669560 — intervention group
Group type: EXPERIMENTAL
Intervention: Open hernia repair
Number of subjects: 200
Study 31670288 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus-32 microparticles with EUS guidance in combination with gemcitabine ± nab-paclitaxel
Number of subjects: 0
Study 31670336 — intervention group
Group type: EXPERIMENTAL
Intervention: DWS with 25% faba bean flour (FBF)
Number of subjects: 54
Study 31670336 — intervention group
Group type: EXPERIMENTAL
Intervention: DWS with 25% starch concentrate (FBS)
Number of subjects: 54
Study 31670336 — intervention group
Group type: EXPERIMENTAL
Intervention: DWS with 25% protein concentrate (FBPC)
Number of subjects: 54
Study 31670336 — intervention group
Group type: EXPERIMENTAL
Intervention: DWS with 25% protein isolate (FBPI)
Number of subjects: 54
Study 31670336 — intervention group
Group type: COMPARATOR
Intervention: DWS alone
Number of subjects: 54
Study 31670336 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 54
Study 31670431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of sense of coherence (SOC)
Number of subjects: 43
Study 31670431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of health-related quality of life (HRQOL) using FACT-G
Number of subjects: 43
Study 31670431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of neurotoxicity using OANQ
Number of subjects: 43
Study 31670431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of physical wellbeing
Number of subjects: 43
Study 31670431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based reporting of social wellbeing
Number of subjects: 43
Study 31670483 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) encompassing eight SNPs in seven genes
Number of subjects: 1000
Study 31670697 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination for estimating cardiac function
Number of subjects: 1075
Study 31670697 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline administration
Number of subjects: 1075
Study 31670697 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of delayed capillary refill time or mottling
Number of subjects: 1075
Study 31670928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 1316
Study 31670928 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per 1 year increase)
Number of subjects: 1316
Study 31670928 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 1316
Study 31670928 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission Alberta Stroke Program Early CT Score (per a decrease of 1 point)
Number of subjects: 1316
Study 31670928 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 1316
Study 31670928 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic poor collaterals
Number of subjects: 1316
Study 31670928 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization in new territory
Number of subjects: 1316
Study 31671877 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose Intensive Rituximab and High-Dose Methylprednisolone
Number of subjects: 0
Study 31672031 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 8582
Study 31672031 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers with HPR
Number of subjects: 8582
Study 31672031 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 8582
Study 31672031 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR)
Number of subjects: 8582
Study 31672100 — intervention group
Group type: EXPERIMENTAL
Intervention: Early LV recovery (within 10 days after the acute event)
Number of subjects: 406
Study 31672100 — intervention group
Group type: COMPARATOR
Intervention: Late LV improvement (after 10 days)
Number of subjects: 406
Study 31672100 — intervention group
Group type: COMPARATOR
Intervention: Patients without early recovery
Number of subjects: 406
Study 31672144 — intervention group
Group type: EXPERIMENTAL
Intervention: BSL ≥ 11.1 mmol/L
Number of subjects: 2168
Study 31672144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyr61 biomarker
Number of subjects: 2168
Study 31672144 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes and elevated entry glucose
Number of subjects: 2168
Study 31672144 — intervention group
Group type: COMPARATOR
Intervention: BSL < 6.0 mmol/L or 6.0-11.1 mmol/L
Number of subjects: 2168
Study 31672148 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 quartile I (< 136 ng/mL)
Number of subjects: 539
Study 31672148 — intervention group
Group type: COMPARATOR
Intervention: PCSK9 quartile IV (> 266 ng/mL)
Number of subjects: 539
Study 31672148 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 levels
Number of subjects: 539
Study 31672665 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial RT-PCR for ZIKV and DENV at 3 timepoints between days 3 and 13 of symptom onset
Number of subjects: 0
Study 31672665 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial serology measurements
Number of subjects: 0
Study 31672665 — intervention group
Group type: COMPARATOR
Intervention: Manufacturers cutoffs for serology
Number of subjects: 0
Study 31672853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PIVKA-II and AFP
Number of subjects: 11
Study 31672853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram including AFP, PIVKA-II, age, and sex
Number of subjects: 11
Study 31672925 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 164
Study 31673295 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-µg vitamin D for 3 months
Number of subjects: 48
Study 31673295 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 48
Study 31673391 — intervention group
Group type: EXPERIMENTAL
Intervention: tocilizumab
Number of subjects: 200
Study 31673391 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 200
Study 31673387 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty (BAV)
Number of subjects: 196
Study 31673387 — intervention group
Group type: COMPARATOR
Intervention: No balloon aortic valvuloplasty (BAV)
Number of subjects: 196
Study 31673398 — intervention group
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY-HC-DM intervention
Number of subjects: 50
Study 31673398 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 31673393 — intervention group
Group type: EXPERIMENTAL
Intervention: USPIO (ferumoxytol, 4 mg/kg) infusion
Number of subjects: 11
Study 31673415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg subcutaneously once every 2 weeks
Number of subjects: 320
Study 31673422 — intervention group
Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine inflammation score
Number of subjects: 40
Study 31673422 — intervention group
Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine fat score
Number of subjects: 40
Study 31673422 — intervention group
Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine bone erosion score
Number of subjects: 40
Study 31673422 — intervention group
Group type: EXPERIMENTAL
Intervention: CANDEN MRI spine new bone formation score
Number of subjects: 40
Study 31673426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) delivered to the target lesion with a cumulative dose of 114 Gy (equivalent dose in 2 Gy with an alpha to beta ratio of 2.6).
Number of subjects: 17
Study 31673426 — intervention group
Group type: COMPARATOR
Intervention: Control lesion (untreated lesion).
Number of subjects: 17
Study 31673426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a fraction size of 10 Gy or greater.
Number of subjects: 17
Study 31673426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT).
Number of subjects: 17
Study 31673900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer therapeutics associated with arrhythmias
Number of subjects: 0
Study 31673946 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-heat-flux sensor (3M Bair Hugger Temperature monitoring system, ZHF)
Number of subjects: 0
Study 31673946 — intervention group
Group type: COMPARATOR
Intervention: Esophageal thermometer
Number of subjects: 0
Study 31673978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) lavage after puncture and lavage of calcification
Number of subjects: 17
Study 31675266 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 31675683 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2+ subtype
Number of subjects: 10595
Study 31675683 — intervention group
Group type: EXPERIMENTAL
Intervention: TNBC subtype
Number of subjects: 10595
Study 31675683 — intervention group
Group type: EXPERIMENTAL
Intervention: Short TFMR
Number of subjects: 10595
Study 31675683 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survivors
Number of subjects: 10595
Study 31675683 — intervention group
Group type: EXPERIMENTAL
Intervention: Median TFMR
Number of subjects: 10595
Study 31675925 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care for cardiovascular risk management (CVRM)
Number of subjects: 740
Study 31675925 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 740
Study 31675952 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 850 mg/m2, P.O. bid, days 1-14, and ziv-aflibercept 6 mg/kg I.V., day 1, of each 21-day cycle
Number of subjects: 50
Study 31675952 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 50
Study 31676085 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 0
Study 31676085 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31676206 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) task of decision making to acquire or discard material possessions
Number of subjects: 79
Study 31676206 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-decision making task contrast
Number of subjects: 79
Study 31676359 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP-adjusted tests for CA19-9
Number of subjects: 504
Study 31676359 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9 levels greater than SNP-determined cut-off values
Number of subjects: 504
Study 31676359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CA19-9 and CEA
Number of subjects: 504
Study 31676359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CA19-9 and CA-125
Number of subjects: 504
Study 31676359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CA19-9 and thrombospondin-2
Number of subjects: 504
Study 31676359 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs for CEA and CA-125
Number of subjects: 504
Study 31676653 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT)
Number of subjects: 20
Study 31676653 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 20
Study 31676905 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid-containing regimens
Number of subjects: 0
Study 31676976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 27
Study 31676976 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pulmonary function testing
Number of subjects: 27
Study 31677135 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated echocardiographic method
Number of subjects: 50
Study 31677135 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual echocardiographic method
Number of subjects: 50
Study 31677135 — intervention group
Group type: COMPARATOR
Intervention: Continuous pulmonary artery thermodilution technique
Number of subjects: 50
Study 31678032 — intervention group
Group type: EXPERIMENTAL
Intervention: LRRK2 non-manifesting carriers
Number of subjects: 392
Study 31678032 — intervention group
Group type: EXPERIMENTAL
Intervention: GBA non-manifesting carriers
Number of subjects: 392
Study 31678093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy
Number of subjects: 1206
Study 31678093 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 1206
Study 31678093 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal myomectomy
Number of subjects: 1206
Study 31678203 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically assisted capsule endoscopy (MACE)
Number of subjects: 50
Study 31678203 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy (EGD)
Number of subjects: 50
Study 31678408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrest (CA) patients
Number of subjects: 1561
Study 31678408 — intervention group
Group type: COMPARATOR
Intervention: Non-cardiac arrest (non-CA) patients
Number of subjects: 1561
Study 31678768 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0
Study 31678768 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31678771 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus after hepatic arterial embolisation therapy (HAET)
Number of subjects: 74
Study 31678771 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus after HAET
Number of subjects: 74
Study 31678771 — intervention group
Group type: EXPERIMENTAL
Intervention: HAET and everolimus
Number of subjects: 74
Study 31678861 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Number of subjects: 64
Study 31679129 — intervention group
Group type: EXPERIMENTAL
Intervention: New injectable treatment for T2DM
Number of subjects: 7
Study 31679176 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular assessment of mucosal biopsies (3BMBs) using unsupervised machine learning algorithms to classify rejection-related phenotypes.
Number of subjects: 243
Study 31679176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection phenotype scoring based on expression of rejection-associated transcripts.
Number of subjects: 243
Study 31679176 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of late inflammation phenotype in 3BMBs.
Number of subjects: 243
Study 31679507 — intervention group
Group type: EXPERIMENTAL
Intervention: PAHEPI program (Treatment 1)
Number of subjects: 320
Study 31679507 — intervention group
Group type: EXPERIMENTAL
Intervention: PAHEPI + school meals (Treatment 2)
Number of subjects: 320
Study 31679701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vessel-sealing device
Number of subjects: 150
Study 31679701 — intervention group
Group type: COMPARATOR
Intervention: Endostaplers
Number of subjects: 150
Study 31679960 — intervention group
Group type: EXPERIMENTAL
Intervention: N170 response to faces
Number of subjects: 77
Study 31679960 — intervention group
Group type: COMPARATOR
Intervention: Social skills intervention
Number of subjects: 77
Study 31680143 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 136
Study 31680143 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic agents
Number of subjects: 136
Study 31680746 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulotomy with capsular conservation
Number of subjects: 2
Study 31680746 — intervention group
Group type: COMPARATOR
Intervention: Capsulectomy
Number of subjects: 2
Study 31680935 — intervention group
Group type: EXPERIMENTAL
Intervention: State-of-the-art MRI techniques for measuring cerebrovascular reactivity (CVR) in large intracranial vessels.
Number of subjects: 0
Study 31681030 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic 3D analysis
Number of subjects: 0
Study 31681165 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteocalcin (OC) levels
Number of subjects: 99
Study 31681600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-radiotherapy with triapine
Number of subjects: 26
Study 31681600 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-radiotherapy without triapine (control)
Number of subjects: 26
Study 31682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 2 years or until disease progression, unacceptable toxicity, or patient withdrawal
Number of subjects: 233
Study 31682588 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise with blood flow restriction (KAATSU training) at 20% of 1 repetition maximum for 12 weeks
Number of subjects: 26
Study 31682588 — intervention group
Group type: COMPARATOR
Intervention: Conventional resistance exercise at 60% of 1 repetition maximum for 12 weeks
Number of subjects: 26
Study 31682827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal MRI
Number of subjects: 0
Study 31682879 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir for 8 weeks
Number of subjects: 343
Study 31682968 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI- and PET-guided interstitial brachytherapy
Number of subjects: 60
Study 31684094 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) intravenous furosemide (greater than 125 mg)
Number of subjects: 121
Study 31684094 — intervention group
Group type: COMPARATOR
Intervention: Low dose (LD) intravenous furosemide (less than 125 mg)
Number of subjects: 121
Study 31684877 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia induction with midazolam, sufentanil, and rocuronium, followed by sevoflurane, with positive pressure ventilation (PEEP 5, tidal volume 6-8 ml/kg)
Number of subjects: 53